Glaucocalyxin a A and FasL and Apoptosis Induction through the JNK Pathway in Human Breast Cancer Cells

Mei Li,Xiao-Gang Jiang,Zhen-Lun Gu,Zu-Bin Zhang

2013-01-01

Abstract:Breast cancer is the most common malignant tumor in women in recent years. It is estimated that more than one million new cases of breast cancer are diagnosed every year in the world, and that about half of these patients would die of this disease. Estrogen therapy is frequently used in the early-stage of breast cancer (Jemal et al., 2011). However, because of the drug resistance, breast cancer is highly resistant to estrogen as the pathology progresses (Miyoshi et al., 2010). Radiotherapy is also used after breast-conserving surgery to decrease the chance of recurrence (Veronesi et al., 2010). Nevertheless, novel therapies and chemo-therapeutic drugs are urgently needed to be developed for the treatment of breast cancer. Apoptosis, which is characterized by cytoplasmic shrinkage, chromatin condensation and DNA fragmentation, is an active form of cell death that occurs in response to several agents, including anticancer chemotherapeutic drugs (Lawen et al., 2003). Many biomarkers and events, such as the caspase family proteins and Bcl-2 family members, could be considered as the determinants of apoptosis (Antonsson et al., 2000). The abnormal production of the molecule may trigger redox signaling pathways, such as oxidative stress, cell cycle arrest and apoptosis (Zhang et al., 2013).